Internal Medicine, Rheumatology · San Antonio, TX
NPI
1376512368
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
5414 Fredericksburg Rd Ste 150
San Antonio, TX, 78229
Phone (210) 615-9800
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
62,416 services
Medicare patients, 2024
691
Average age 72
Drug cost, 2024
$3.9M
3,785 prescriptions
Company payments, 2025
$2,862
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Emily R Pineda was code J0129 (injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 9,626 times for 14 patients. In total Emily R Pineda billed 62,416 services in 47 codes, and Medicare paid $1.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-10-07.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 9,626 | 14 | $33.92 | $327K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 9,200 | 14 | $8.77 | $81K |
| J0897 Injection, denosumab, 1 mg | Office | 4,440 | 44 | $20.31 | $90K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,401 | 35 | $0.10 | $232 |
| 99214 Office E&M - Established | Office | 1,603 | 640 | $84.43 | $135K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,052 | 177 | $0.74 | $775 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,008 | 524 | $11.26 | $11K |
| 96413 Chemotherapy Administration | Office | 307 | 49 | $89.02 | $27K |
| 20611 Joint Injection | Office | 285 | 106 | $66.59 | $19K |
| 96401 Chemotherapy Administration | Office | 197 | 47 | $48.11 | $9,478 |
| 96415 Chemotherapy Administration | Office | 126 | 14 | $17.25 | $2,173 |
| 99204 Office E&M - New | Office | 112 | 112 | $112.60 | $13K |
| 20604 Joint Injection | Office | 71 | 52 | $56.85 | $4,037 |
| 96375 Injection Administration | Office | 67 | 11 | $7.72 | $517 |
| J7323 Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | Office | 45 | 12 | $82.59 | $3,717 |
By year: 2022 $1.2M for 68,860 services; 2023 $1.1M for 62,385 services; 2024 $1.1M for 62,416 services.
Medicare prescription drug claims, 2024
In 2024, the drug Emily R Pineda prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 660 prescriptions and refills. In total Emily R Pineda wrote 3,785 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 660 | 1,374 | 198 | $20K |
| Progesterone Progesterone, Micronized | 333 | 648 | 86 | $32K |
| Methotrexate Methotrexate Sodium | 249 | 581 | 90 | $7,292 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 212 | 212 | 28 | $6,071 |
| Leucovorin Calcium Generic | 140 | 298 | 49 | $11K |
| Tramadol Hcl Generic | 124 | 124 | 20 | $1,085 |
| Levothyroxine Sodium Generic | 122 | 243 | 31 | $1,206 |
| Leflunomide Generic | 120 | 289 | 36 | $5,866 |
| Estradiol Generic | 96 | 246 | 27 | $2,708 |
| Mycophenolate Mofetil Generic | 82 | 169 | 19 | $12K |
| Duloxetine Hcl Generic | 74 | 136 | 17 | $1,819 |
| Np Thyroid Thyroid,pork | 74 | 121 | 21 | $4,130 |
| Cyclobenzaprine Hcl Generic | 72 | 114 | 15 | $1,238 |
| Sulfasalazine Generic | 71 | 166 | 23 | $2,172 |
| Pregabalin Generic | 71 | 102 | 18 | $1,861 |
Brand drugs: 607 claims; generic drugs: 3,011 claims; opioid claims: 375.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Emily R Pineda $2,862 ($2,862 in general payments such as food, travel and fees) from 12 companies. The largest payer was Amgen Inc. with $532.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 26 | $532 |
| Janssen Biotech, Inc. JNJ | 15 | $464 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $343 |
| Abbvie Inc. ABBV | 15 | $278 |
| UCB, Inc. UCB.BR | 8 | $274 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $248 |
| Mallinckrodt Hospital Products Inc. | 9 | $230 |
| Genzyme Corporation SNY | 7 | $199 |
| GlaxoSmithKline, LLC. GSK | 8 | $137 |
| Radius Health, Inc. | 3 | $83.38 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.